tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Denys-Drash Syndrome D030321 1 associated lipids
Hypophosphatemia D017674 1 associated lipids
Moyamoya Disease D009072 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Leukoplakia D007971 1 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Scorpion Stings D065008 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Mediastinitis D008480 2 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Ileus D045823 3 associated lipids
Rectal Diseases D012002 1 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Doi R et al. Biochemical characterization of the effects of FK506 on signal transduction in exocytotic function of rat pancreatic acini. 1993 J. Pharmacol. Exp. Ther. pmid:7679738
Gunji Y et al. Pathologic characteristics of vasculitis in renal transplant recipient dogs receiving immunosuppressive agents, FK 506, rapamycin, or RS-61443. 1993 Transplant. Proc. pmid:7679841
Gregory CR et al. Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo. 1993 Transplant. Proc. pmid:7679842
Zeevi A et al. Comparative in vitro studies on the immunosuppressive effects of purine and pyrimidine synthesis inhibitors. 1993 Transplant. Proc. pmid:7679843
Inoue T et al. Isolation of mitochondrial cyclophilin from bovine heart. 1993 Biochem. Biophys. Res. Commun. pmid:7679902
Woodle ES et al. FK506--reversal of humorally mediated cardiac allograft rejection in the presence of preformed anti-class I antibody. 1993 Transplantation pmid:7504346
Jindal RM et al. Effect of deoxyspergualin on the endocrine function of the rat pancreas. 1993 Transplantation pmid:7504347
Kodama M et al. FK506 therapy of experimental autoimmune myocarditis after onset of the disease. 1993 Am. Heart J. pmid:7504393
Luan S et al. Immunosuppressants implicate protein phosphatase regulation of K+ channels in guard cells. 1993 Proc. Natl. Acad. Sci. U.S.A. pmid:7681590
Doi R et al. Structural and functional changes of exocrine pancreas induced by FK506 in rats. 1993 Gastroenterology pmid:7681795
Rotonda J et al. Improved calcineurin inhibition by yeast FKBP12-drug complexes. Crystallographic and functional analysis. 1993 J. Biol. Chem. pmid:7681823
Simek SL et al. Sequence and localization of a novel FK506-binding protein to mouse chromosome 11. 1993 Genomics pmid:7507077
Quesniaux VF Immunosuppressants: tools to investigate the physiological role of cytokines. 1993 Bioessays pmid:7507316
Hill CC et al. Penile prosthesis surgery in the immunosuppressed patient. 1993 Transplantation pmid:7692633
Roberts JP et al. Reversal of chronic rejection after treatment failure with FK506 and RS61443. 1993 Transplantation pmid:7692634
Storb R et al. FK-506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen-nonidentical donors. 1993 Transplantation pmid:7692635
McDiarmid SV et al. A comparison of renal function in cyclosporine- and FK-506-treated patients after primary orthotopic liver transplantation. 1993 Transplantation pmid:7692636
Clipstone NA and Crabtree GR Calcineurin is a key signaling enzyme in T lymphocyte activation and the target of the immunosuppressive drugs cyclosporin A and FK506. 1993 Ann. N. Y. Acad. Sci. pmid:7509131
Takahara S Efficacy of FK506 in renal transplantation. 1993 Ann. N. Y. Acad. Sci. pmid:7509132
Thomson AW et al. Incidence of CD4+ IL-2R alpha+ and CD4+ CD45RA+ T-cells in progressive multiple sclerosis and the influence of short-term (3 months) FK 506 therapy. 1993 Ann. N. Y. Acad. Sci. pmid:7509133
Denesyuk AI et al. Structural similarity of the binding sites of cyclophilin A-cyclosporin A and FKBP-FK506 systems. 1993 Biochem. Biophys. Res. Commun. pmid:7683466
Waschulewski IH et al. Effects of the immunosuppressants cyclosporin A and FK 506 on exocytosis in the rat exocrine pancreas in vitro. 1993 Br. J. Pharmacol. pmid:7683567
Ohtake M et al. Enhanced liver regeneration in rats treated with 15-deoxyspergualin alone and in combination with FK 506. 1993 Gastroenterol. Jpn. pmid:7683616
Ohnishi H et al. Natural killer cell may impair liver regeneration in fulminant hepatic failure. 1993 Gastroenterol. Jpn. pmid:7683619
Murphy MP and Morris RE Brequinar sodium effectively and potently suppresses allograft rejection in a heterotopic mouse heart transplant model. 1993 Transplant. Proc. pmid:7685955
Li W and Handschumacher RE Specific interaction of the cyclophilin-cyclosporin complex with the B subunit of calcineurin. 1993 J. Biol. Chem. pmid:7686148
Wong PY et al. Recurrence of primary biliary cirrhosis after liver transplantation following FK506-based immunosuppression. 1993 J. Hepatol. pmid:7686192
Sakr MF et al. FK 506 pre-treatment is associated with reduced levels of tumor necrosis factor and interleukin 6 following hepatic ischemia/reperfusion. 1993 J. Hepatol. pmid:7686193
Jacobs JC et al. Pyoderma gangrenosum in infancy. 1993 J. Am. Acad. Dermatol. pmid:7688775
Garrity GM et al. Genetic relationships among actinomycetes that produce the immunosuppressant macrolides FK506, FK520/FK523 and rapamycin. 1993 J. Ind. Microbiol. pmid:7688970
Hoof T et al. Reversal of multidrug resistance in Chinese hamster ovary cells by the immunosuppressive agent rapamycin. 1993 Eur. J. Pharmacol. pmid:7689059
Jin YJ and Burakoff SJ The 25-kDa FK506-binding protein is localized in the nucleus and associates with casein kinase II and nucleolin. 1993 Proc. Natl. Acad. Sci. U.S.A. pmid:7689229
McMichael J et al. An intelligent and cost-effective computer dosing system for individualizing FK506 therapy in transplantation and autoimmune disorders. 1993 J Clin Pharmacol pmid:7690046
Jain AB et al. Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion. 1993 J Clin Pharmacol pmid:7690047
Cheng JW et al. 15N NMR relaxation studies of the FK506 binding protein: backbone dynamics of the uncomplexed receptor. 1993 Biochemistry pmid:7690248
Langrehr JM et al. Clinical course, morphology, and treatment of chronically rejecting small bowel allografts. 1993 Transplantation pmid:7679526
Uemoto S et al. Experience with FK506 in living-related liver transplantation. 1993 Transplantation pmid:7679528
Talento A et al. A single administration of LFA-1 antibody confers prolonged allograft survival. 1993 Transplantation pmid:7679531
Sattler M et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. 1992 Sep-Oct Drug Metab. Dispos. pmid:1385058
Bowman H and Lennard TW Immunosuppressive drugs. 1992 Nov 4-17 Br J Hosp Med pmid:1282440
Nazer H et al. FK 506 associated disorders in liver transplantation. 1992 May-Jun J. Gastroenterol. Hepatol. pmid:1377038
Arai S et al. The impact of FK506 on graft coronary disease of rat cardiac allograft--a comparison with cyclosporine. 1992 Jul-Aug J. Heart Lung Transplant. pmid:1379829
Fagiuoli S et al. FK 506: a new immunosuppressive agent for organ transplantation. Pharmacology, mechanism of action and clinical applications. 1992 Jul-Aug Ital J Gastroenterol pmid:1381245
Tong J et al. Effect of FK-506 and cyclosporin A on in vitro CFU-GM growth in severe aplastic anemia patients. 1992 Jul-Aug Haematologica pmid:1385279
Mizuno K et al. Modulation of multidrug resistance by immunosuppressive agents: cyclosporin analogues, FK506 and mizoribine. 1992 Jan-Feb Anticancer Res. pmid:1373592
Chen TS et al. Microbial transformation of immunosuppressive compounds. I. Desmethylation of FK506 and immunomycin (FR 900520) by Actinoplanes sp. ATCC 53771. 1992 J. Antibiot. pmid:1372307
Sigal NH and Dumont FJ Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. 1992 Annu. Rev. Immunol. pmid:1375473
Minoda M et al. Effects of gamma-interferon and FK506 on resting B cell proliferation of New Zealand black/white F1 mice. 1992 Microbiol. Immunol. pmid:1282197
Fukuse T et al. Optimal dose of FK 506 in canine lung allotransplantation. 1992 Transplant. Proc. pmid:1379757
Arceci RJ et al. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. 1992 Blood pmid:1381629